Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the operating margin high or low?
The operating margin of -305.03% is 17% below its 5-year average of -261.71%, near the high end of its 5-year range (-1431.63%–0.00%).
3.63% above its 12-month average of -316.52%.
Reported quarterly operating margin; no daily interpolation. Q4 FY2026 (2026-06-30): -367.46%.
OPERATING MARGIN
-305.03%
OPERATING MARGIN AVG TTM
-316.52%
OPERATING MARGIN AVG 3Y
-331.60%
OPERATING MARGIN AVG 5Y
-261.71%
OPERATING MARGIN AVG 10Y
N/A
OPERATING MARGIN AVG 15Y
N/A
OPERATING MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+3.63%
CURRENT VS 3Y AVG
+8.01%
CURRENT VS 5Y AVG
-16.55%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Intelligent Bio Solutions Inc.
Market Cap
$5.24M
Operating Margin
-305.03%
TTM Avg
-316.52%
3Y Avg
-331.60%
5Y Avg
-261.71%
Market Cap
$5.22M
Operating Margin
0.00%
TTM Avg
-62.53%
3Y Avg
-159.78%
5Y Avg
-184.56%
Market Cap
$5.21M
Operating Margin
-19.28%
TTM Avg
1.28%
3Y Avg
11.60%
5Y Avg
11.60%
Market Cap
$5.21M
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$5.31M
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
-1423.89%
5Y Avg
-7655.73%
Market Cap
$5.32M
Operating Margin
-3317.65%
TTM Avg
-1658.83%
3Y Avg
-2341.84%
5Y Avg
-1561.23%
Market Cap
$5.35M
Operating Margin
-1683.01%
TTM Avg
-1461.09%
3Y Avg
-2100.59%
5Y Avg
-1711.35%
Market Cap
$5.12M
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$4.97M
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | OPERATING MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Intelligent Bio Solutions Inc. (INBS) | $5.24M | -305.03% | -316.52% | -331.60% | -261.71% |
| Pulmatrix, Inc. (PULM)vs › | $5.22M | 0.00% | -62.53% | -159.78% | -184.56% |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.21M | -19.28% | 1.28% | 11.60% | 11.60% |
| Alzamend Neuro Inc (ALZN)vs › | $5.21M | 0.00% | 0.00% | 0.00% | 0.00% |
| Soligenix, Inc. (SNGX)vs › | $5.31M | 0.00% | 0.00% | -1423.89% | -7655.73% |
| Gelteq Limited Ordinary Shares (GELS)vs › | $5.32M | -3317.65% | -1658.83% | -2341.84% | -1561.23% |
| Lexaria Bioscience Corp. (LEXX)vs › | $5.35M | -1683.01% | -1461.09% | -2100.59% | -1711.35% |
| Lunai Bioworks Inc. (LNAI)vs › | $5.12M | 0.00% | 0.00% | 0.00% | 0.00% |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $4.97M | 0.00% | 0.00% | 0.00% | 0.00% |
| Xenetic Biosciences, Inc. (XBIO)vs › | $4.86M | -95.23% | -131.69% | -208.69% | -753.28% |
Gross Margin
48.6%
Operating Margin
-305.0%
Operating Margin = Operating Income / Revenue
Operating margin is the percentage of revenue remaining after operating expenses, reflecting operating efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | OPERATING MARGIN |
|---|---|
| 2026-06-30 | -367.46% |
| 2026-03-31 | -292.95% |
| 2025-12-31 | -290.89% |
| 2025-09-30 | -263.63% |
| 2025-06-30 | -367.66% |
| 2025-03-31 | -374.08% |
| 2024-12-31 | -372.76% |
| 2024-09-30 | -326.89% |
| 2024-06-30 | -386.32% |
| 2024-03-31 | -358.55% |
| 2023-12-31 | -260.63% |
| 2023-09-30 | -317.35% |
| 2023-06-30 | -604.63% |
| 2023-03-31 | -1431.63% |
| 2022-12-31 | -597.45% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | -53.03% |
| 2021-03-31 | -9158.69% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | -1196.16% |
| 2020-06-30 | -737.53% |
| 2020-03-31 | 1880.23% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 2514.91% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 0.00% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | 202529.03% |
